Intended for healthcare professionals


China rejects patent on hepatitis C drug sofosbuvir

BMJ 2015; 350 doi: (Published 23 June 2015) Cite this as: BMJ 2015;350:h3429
  1. Zosia Kmietowicz
  1. 1The BMJ

The Chinese patent office has rejected a patent application for the blockbuster hepatitis C treatment sofosbuvir, increasing the possibility of a generic version of the drug to become available in China.

The decision comes after a challenge by the Initiative for Medicines, Access and Knowledge (I-MAK), a US based group that campaigns for better access to affordable drugs. The group claimed that Gilead Sciences, the US biotechnology company that makes sofosbuvir, which recorded sales of more than $10bn in 2014, was seeking “illegitimate patents” for sofosbuvir and “blocking millions …

View Full Text

Log in

Log in through your institution


* For online subscription